Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once vs Three Times Weekly Recormon in Dialysis Patients
NCT01111630Phase 4Completed
- Sponsor
- JW Pharmaceutical Corporation
- Start
- Oct 2009
- Primary completion
- Oct 2013
- Modality
- Erythropoietins, Colony Stimulating Factors
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of epoetin beta in anemia of chronic kidney disease (2 arms), sponsored by JW Pharmaceutical Corporation. Primary endpoint: The hemoglobin variability between once & three times weekly administration at 24 weeks. Started Oct 2009; status: completed.
02
Drugs
epoetin beta
03
Conditions
anemia of chronic kidney disease
Beyond the preview
Go deeper on NCT01111630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111630.